BioLASCO Taiwan Co., Ltd. (TPEX:6662)
Taiwan · Delayed Price · Currency is TWD 29.90
-0.50 (-1.64%)
Apr 20, 2026, 1:09 PM CST
BioLASCO Taiwan Revenue
In the year 2025, BioLASCO Taiwan had annual revenue of 262.66M TWD, down -10.20%. BioLASCO Taiwan had revenue of 69.29M in the quarter ending December 31, 2025, a decrease of -17.26%.
Revenue
262.66M
Revenue Growth
-10.20%
P/S Ratio
2.92
Revenue / Employee
2.89M
Employees
91
Market Cap
765.80M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 262.66M | -29.83M | -10.20% |
| Dec 31, 2024 | 292.50M | 27.78M | 10.49% |
| Dec 31, 2023 | 264.72M | 28.81M | 12.21% |
| Dec 31, 2022 | 235.91M | 8.33M | 3.66% |
| Dec 31, 2021 | 227.58M | -71.30M | -23.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Level Biotechnology | 736.59M |
| Taiwan Advance Bio-Pharmaceutical | 371.86M |
| TCI GENE | 273.61M |
| GeneReach Biotechnology | 232.74M |
| Lukas Biomedical | 180.32M |
| NatureWise Biotech & Medicals | 180.29M |
| Vectorite Biomedical | 67.90M |
| Holy Stone Healthcare | 47.51M |